The patent also covers the polypeptide and nucleotide composition of matter for davunetide, its parent protein activity-dependent neuroprotective protein (ADNP) and other derivatives of ADNP.
Currently, davunetide is being evaluated in a Phase 2/3 clinical trial as a potential treatment for progressive supranuclear palsy (PSP), a rapidly progressing and fatal degenerative brain disease often misdiagnosed as Parkinson’s or Alzheimer’s disease.
Allon Therapeutics vice president of Commercial Research Alistair Stewart said the Japanese patent expands the davunetide’s commercial market potential beyond North America and Europe.
"Davunetide’s clinical development has reached the stage where its commercialization is on the horizon, and the patent portfolio becomes critical to efforts in attracting pharma companies which are potential commercialization partners," said Stewart.
Allon Therapeutics has been granted another patent in the US for davunetide use to treat fetal alcohol syndrome.